GlassScriptPhysician profile
Jeeten Jamnadas
NPI 1205327392
$1,060.88
in general payments reported to CMS, 2019-2025
12 companies · $449 in 2025
The $449 reported for 2025 was less than what a typical Sleep Medicine (Family Medicine) provider received nationally (typical 2025 total: $557).
See the full distribution for Sleep Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.82 · 2020: $15.04 · 2022: $18.83 · 2023: $311 · 2024: $227 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $667 · Education: $170 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $667.21 |
| Education | $169.98 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $707.64 | 2023-2025 | |
| Harmony Biosciences LLC | $50.90 | 2023-2024 | Wakix |
| Inspire Medical Systems, INC. | $50.89 | 2023-2025 | Inspire |
| Atricure, INC. | $50.28 | 2025 | Synergy Ablation System |
| E.R. Squibb & Sons, L.L.C. | $49.32 | 2022-2023 | Camzyos |
| Janssen Pharmaceuticals, INC | $37.04 | 2019-2023 | Xarelto |
| Cvrx, INC. | $22.24 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $21.25 | 2025 | Verquvo |
| Corcept Therapeutics | $19.91 | 2025 | Korlym |
| 3b Medical, INC. | $19.36 | 2024 | Luna |
| Novartis Pharmaceuticals Corporation | $17.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.04 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeeten Jamnadas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.